Statement: Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 672/2264 (29.68%)   Febrile neutropenia * 117/2264 (5.17%)   Neutropenia * 98/2264 (4.33%)   Febrile bone marrow aplasia * 14/2264 (0.62%)   Anaemia * 8/2264 (0.35%)   Leukopenia * 8/2264 (0.35%)   Thrombocytopenia * 6/2264 (0.27%)   Disseminated intravascular coagulation * 3/2264 (0.13%)   Agranulocytosis * 1/2264 (0.04%)   Bone marrow failure * 1/2264 (0.04%)